Competition between CTL narrows the immune response induced by prime-boost vaccination protocols

被引:135
作者
Palmowski, MJ
Choi, EML
Hermans, IF
Gilbert, SC
Chen, JL
Gileadi, U
Salio, M
Van Pel, A
Man, S
Bonin, E
Liljestrom, P
Dunbar, PR
Cerundolo, V [1 ]
机构
[1] John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DS, England
[2] Wellcome Trust Ctr Human Genet, Oxford, England
[3] Catholic Univ Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium
[4] Cardiff Univ, Dept Med, Cardiff CF4 4XN, S Glam, Wales
[5] Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden
关键词
D O I
10.4049/jimmunol.168.9.4391
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recombinant vaccines encoding strings of virus- or tumor-derived peptides and/or proteins are currently being designed for use against both cancer and infectious diseases. These vaccines aim to induce cytotoxic immune responses against several Ags simultaneously. We developed a novel tetramer-based technique, based on chimeric HLA A2/H-2K(b) H chains, to directly monitor the CTL response to such vaccines in HLA-A2 transgenic mice. We found that priming and boosting with the same polyepitope construct induced immune responses that were dominated by CTL of a single specificity. When a mixture of viruses encoding single proteins was used to boost the polyepitope primed response, CTL of multiple specificities were simultaneously expanded to highly effective levels in vivo. In addition, we show that a preexisting response to one of the epitopes encoded within a polyepitope construct significantly impaired the ability of the vaccine to expand CTL of other specificities. Our findings define a novel vaccination strategy optimized for the induction of an effective polyvalent cytotoxic response.
引用
收藏
页码:4391 / 4398
页数:8
相关论文
共 48 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[3]  
Barchet W, 2000, EUR J IMMUNOL, V30, P1356, DOI 10.1002/(SICI)1521-4141(200005)30:5<1356::AID-IMMU1356>3.0.CO
[4]  
2-K
[5]   Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice [J].
Berglund, P ;
Fleeton, MN ;
Smerdou, C ;
Liljeström, P .
VACCINE, 1999, 17 (05) :497-507
[6]   Enhancing immune responses using suicidal DNA vaccines [J].
Berglund, P ;
Smerdou, C ;
Fleeton, MN ;
Tubulekas, I ;
Liljeström, P .
NATURE BIOTECHNOLOGY, 1998, 16 (06) :562-565
[7]   Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model [J].
Carroll, MW ;
Overwijk, WW ;
Chamberlain, RS ;
Rosenberg, SA ;
Moss, B ;
Restifo, NP .
VACCINE, 1997, 15 (04) :387-394
[8]  
DEL VM, 1991, CELL, V66, P1145
[9]   A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response [J].
Dunbar, PR ;
Smith, CL ;
Chao, D ;
Salio, M ;
Shepherd, D ;
Mirza, F ;
Lipp, M ;
Lanzavecchia, A ;
Sallusto, F ;
Evans, A ;
Russell-Jones, R ;
Harris, AL ;
Cerundolo, V .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6644-6652
[10]  
Dunbar PR, 1999, J IMMUNOL, V162, P6959